X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $42.12 | -3,323 | 146,202 | -2% | -$139,973 | |||||
| D | 2024-10-21 | RNA | Levin Arthur A | Dir | S - Sale+OE | $46.63 | -5,000 | 146,202 | -3% | -$233,168 | |||||
| D | 2024-09-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.73 | -5,000 | 146,202 | -3% | -$228,658 | |||||
| D | 2024-08-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.19 | -5,000 | 168,702 | -3% | -$225,947 | |||||
| D | 2024-07-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $45.01 | -5,000 | 168,702 | -3% | -$225,069 | |||||
| D | 2024-06-20 | RNA | Levin Arthur A | Dir | S - Sale+OE | $37.59 | -5,000 | 168,702 | -3% | -$187,951 | |||||
| DM | 2024-06-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $38.07 | -100,000 | 168,702 | -37% | -$3,807,410 | |||||
| D | 2024-05-20 | RNA | Levin Arthur A | Dir | S - Sale+OE | $29.90 | -5,000 | 268,702 | -2% | -$149,481 | |||||
| D | 2024-04-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.82 | -5,000 | 268,702 | -2% | -$114,123 | |||||
2024-04-03 | RNA | Levin Arthur A | Dir | S - Sale | $27.11 | -20,000 | 268,702 | -7% | -$542,214 | ||||||
| D | 2024-03-19 | RNA | Levin Arthur A | Dir | S - Sale+OE | $23.97 | -5,000 | 288,702 | -2% | -$119,848 | |||||
| D | 2024-03-12 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.03 | -27,641 | 288,702 | -9% | -$609,017 | |||||
2024-01-22 | RNA | Levin Arthur A | Dir | S - Sale | $10.13 | -1,859 | 291,343 | -1% | -$18,832 | ||||||
| D | 2023-03-15 | RNA | Levin Arthur A | Dir | S - Sale+OE | $22.01 | -100 | 293,202 | 0% | -$2,201 | |||||
| D | 2023-02-14 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $23.66 | -10,000 | 293,202 | -3% | -$236,567 | |||||
| D | 2023-01-12 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.00 | -10,000 | 275,202 | -4% | -$220,028 | |||||
| D | 2022-12-29 | RNA | Levin Arthur A | Chief Scientific Officer | S - Sale+OE | $22.01 | -40,000 | 1,330 | -97% | -$880,568 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |